Browse the evidence

In obesity, the accumulation of classically activated (M1) macrophages in adipose tissue drives insulin resistance through the secretion of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and the activation of stress kinases (JNK, IKK, p38 MAPK) that inhibit insulin receptor signaling.

Obesity triggers an immune response in fat tissue where immune cells (M1 macrophages) become inflamed and block insulin's ability to work. This happens because excess fat releases signals that activate these immune cells. Managing body weight and reducing fat mass can help reverse this inflammatory state and improve insulin sensitivity.

M2 macrophages in lean adipose tissue maintain insulin sensitivity by secreting anti-inflammatory cytokines (IL-10, TGF-β) and utilizing oxidative metabolism, whereas obesity shifts this balance toward M1.

Maintaining a healthy weight helps preserve M2 macrophages in fat tissue, which actively protect against insulin resistance by reducing inflammation and supporting metabolic health.

Obesity-associated insulin resistance is driven by the failure of adipose tissue expandability, which causes nutrient leakage and lipotoxicity in non-adipose organs, rather than by adipose mass alone.

Focus on improving adipose tissue health and capacity rather than just reducing total fat mass. Strategies that support safe lipid storage (e.g., through specific dietary patterns or medications that enhance adipose expandability) may be more effective for metabolic health than weight loss alone, which can sometimes exacerbate lipotoxicity if not managed correctly.

Adipose tissue plasticity and the production of specific adipokines (e.g., TNF-alpha, resistin) contribute to insulin resistance by impairing adipose tissue function and limiting further expansion.

Managing obesity may require addressing the hormonal signals from fat tissue, not just the fat itself. Some medications aim to improve adipose tissue function and reduce harmful adipokine production.

Low serum 25-hydroxyvitamin D concentrations (specifically <50 nmol/L) are associated with a significantly increased risk of incident all-cause dementia and Alzheimer's disease in elderly adults.

This study suggests that maintaining vitamin D levels above 50 nmol/L may be associated with a lower risk of dementia in older adults. However, it does not prove that taking supplements will prevent dementia. You should discuss your vitamin D levels with your doctor to ensure they are within a healthy range for your overall health, but do not expect supplements alone to guarantee cognitive protection.

Twelve weeks of combined endurance and strength training in humans does not increase circulating irisin levels and may actually reduce them, despite increasing muscle FNDC5 mRNA expression.

If you are training to boost irisin for fat loss, this 12-week study suggests it won't work as expected; irisin levels actually decreased. However, your muscle genes (PGC1A and FNDC5) did upregulate. Focus on the direct metabolic benefits of exercise rather than expecting a specific hormonal spike in irisin.

Acute exercise (45 min at 70% VO2max) causes a transient ~1.2-fold increase in plasma irisin immediately post-exercise, which returns to baseline within 2 hours.

If you measure irisin right after a hard workout, it will be slightly higher. However, this spike is short-lived and does not persist, suggesting it is not a primary driver of long-term metabolic adaptation via this specific hormone.

Chronic exercise training increases muscle PGC1A and FNDC5 mRNA expression in humans, but this transcriptional increase does not correlate with plasma irisin levels or subcutaneous fat browning (UCP1).

Your muscles do adapt to exercise by increasing the machinery (PGC1A/FNDC5 mRNA) to potentially produce irisin. However, this does not mean more irisin enters your blood or that your fat turns brown. The local muscle changes are real, but the systemic hormonal effect is not.

A simple index derived from the first 30 minutes of an Oral Glucose Tolerance Test (OGTT), calculated as the product of the area under the curve (AUC) for glucose and insulin, accurately quantifies hepatic (liver) insulin resistance.

If you are at risk for diabetes or metabolic syndrome, a standard Oral Glucose Tolerance Test (OGTT) can reveal liver-specific insulin resistance. By analyzing the first 30 minutes of your blood sugar and insulin response, doctors can identify liver dysfunction earlier and more accurately than with fasting tests alone, allowing for targeted lifestyle or medical interventions to prevent type 2 diabetes.

A specific index derived from the decline phase of an Oral Glucose Tolerance Test (OGTT), calculated as the rate of glucose decline divided by mean insulin concentration, accurately quantifies skeletal muscle insulin sensitivity.

If you are at risk for diabetes or metabolic syndrome, a standard Oral Glucose Tolerance Test (OGTT) can reveal muscle-specific insulin resistance. By analyzing how quickly your blood sugar drops after the peak and dividing that by your insulin levels, doctors can identify muscle dysfunction earlier and more accurately than with fasting tests alone, allowing for targeted lifestyle or medical interventions to prevent type 2 diabetes.

Obstructive sleep apnea syndrome (OSAS) is an independent risk factor for stroke and death from any cause, with risk increasing proportionally to the severity of the apnea.

If you have symptoms of sleep apnea (loud snoring, daytime sleepiness), get tested. The condition is not just a nuisance; it independently raises your risk of stroke and death, even if you don't have high blood pressure or are not obese. Treating the apnea is a stroke prevention strategy.

Transdermal estrogen does not significantly increase the risk of venous thromboembolism in postmenopausal women, unlike oral estrogen.

If you are using transdermal estrogen (patches or gels), your risk of blood clots is not significantly increased compared to women not using hormones. This makes transdermal estrogen a safer choice than oral estrogen for postmenopausal women concerned about thromboembolism, especially those with other risk factors like obesity or genetic mutations.

Biliopancreatic diversion (BPD) achieves sustained weight loss and maintenance primarily by establishing a fixed intestinal energy absorption threshold for fat and starch, rather than through caloric restriction or reduced appetite.

This surgical intervention works by physically preventing the absorption of calories from fats and starches, creating a hard ceiling on energy intake regardless of how much you eat. It is not a diet; it is a physiological limit. Patients often regain normal appetite and eat larger volumes, but the weight stabilizes because the excess calories are excreted rather than stored.

BPD induces a specific increase in resting energy expenditure (REE) driven by intestinal adaptation (increased bowel mass and activity), which contributes to weight loss independent of the absorption threshold.

In female patients, BPD may boost your metabolic rate (calories burned at rest) by forcing your intestines to grow and work harder. This increased energy expenditure helps drive weight loss and maintenance, counteracting the typical metabolic slowdown seen with weight loss.

Leptin resistance in obesity is mechanistically linked to the overexpression of negative regulators of leptin signaling, specifically SOCS-3 and PTP1B, in the hypothalamus.

Leptin resistance isn't just about 'willpower'; it involves specific proteins (SOCS-3, PTP1B) that block the signal in your brain. Research is targeting these specific proteins to develop drugs that could restore sensitivity.

Exogenous testosterone therapy increases the risk of cardiovascular-related events in men, with an overall odds ratio of 1.54 compared to placebo.

If you are considering testosterone therapy, be aware that it may increase your risk of cardiovascular events. The overall risk is about 1.5 times higher than placebo. This risk appears higher in trials not funded by pharmaceutical companies. Discuss this risk with your doctor, especially if you have existing heart conditions or are older.

The increased risk of cardiovascular events associated with testosterone therapy is significantly higher in trials not funded by the pharmaceutical industry compared to those that are.

Be cautious about the source of information regarding testosterone safety. Independent studies suggest a higher risk of heart-related events than industry-sponsored studies. If you are taking testosterone, ensure your doctor is monitoring your cardiovascular health closely, especially if you have other risk factors.

Synthetic exendin-4 (exenatide) significantly reduces both fasting and postprandial plasma glucose in patients with type 2 diabetes through glucose-dependent insulin secretion, glucagon suppression, and slowed gastric emptying.

For patients with Type 2 Diabetes, synthetic exendin-4 (exenatide) is an effective treatment that lowers blood sugar both after meals and while fasting. It works by boosting insulin only when blood sugar is high, suppressing excess glucagon, and slowing down how fast food leaves the stomach. While it requires twice-daily injections and may cause temporary nausea, it offers a distinct advantage over some older medications by not causing hypoglycemia and potentially preserving beta-cell function.

Chronic circadian disruption, modeled by housing mice in incongruous 20-hour light/dark cycles, causes accelerated weight gain, obesity, and metabolic dysregulation (elevated insulin and leptin) despite unchanged food consumption.

If you work shifts or have irregular sleep/wake cycles, your body may gain weight and develop insulin resistance even if you don't change your diet. This is because your internal biological clock is desynchronized from your environment. Prioritizing consistent sleep-wake times and light exposure may help mitigate these metabolic risks.

Chronic circadian disruption reduces cognitive flexibility and alters emotionality by causing structural remodeling (loss of dendritic complexity) in the prelimbic prefrontal cortex.

Irregular sleep schedules can physically alter your prefrontal cortex, reducing your ability to adapt to new information and increasing emotional reactivity. Maintaining a consistent sleep-wake cycle, even on days off, protects your brain structure and cognitive flexibility.

Artificial intelligence techniques, including fuzzy logic, neural networks, and reinforcement learning, are effective tools for automating blood glucose control and prediction in diabetes management, improving glycemic outcomes and reducing hypoglycemia risk compared to traditional methods or manual management.

For patients using insulin pumps or continuous glucose monitors (CGM), AI-driven 'artificial pancreas' systems can automatically adjust insulin delivery based on real-time glucose readings. This technology has been shown in multiple studies to improve blood sugar control and reduce dangerous low-blood-sugar events, particularly at night, compared to standard pump therapy. Patients should consult their endocrinologist about AI-integrated devices if they struggle with manual dose calculations or frequent hypoglycemia.

Standard BMI cutoffs (≥30 kg/m²) significantly underestimate obesity prevalence, particularly in women, due to failure to account for sarcopenic obesity and body composition changes with age.

If you are a woman, especially over 50, your BMI might be misleading. You could have 'normal weight obesity' (high body fat, low muscle) which carries health risks. Ask your doctor about body composition analysis (like DXA) or leptin levels if you have risk factors, rather than relying solely on BMI.

Premenopausal women are protected from developing NAFLD due to estrogen-mediated partitioning of fatty acids toward ketone body production and sex-specific browning of white adipose tissue, whereas postmenopausal estrogen deficiency facilitates massive hepatic steatosis and fibrotic progression.

For women, reproductive status is a critical factor in liver health. Before menopause, estrogen helps protect the liver by directing fat away from storage in the liver and towards energy use (ketones). After menopause, this protection vanishes, significantly increasing the risk of fatty liver and scarring, even if weight doesn't change drastically. Maintaining metabolic health becomes even more crucial post-menopause to counteract this hormonal shift.

Postmenopausal women have a higher prevalence of NAFLD than premenopausal women, and this risk is independently associated with menopause status even after adjusting for metabolic factors in some studies.

After menopause, your risk of fatty liver disease increases significantly, even if you maintain a healthy weight. This is largely due to the loss of estrogen. Regular liver health monitoring is recommended for postmenopausal women.